Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
Add more filters










Publication year range
1.
J Appl Toxicol ; 28(4): 422-9, 2008 May.
Article in English | MEDLINE | ID: mdl-18344198

ABSTRACT

Oximes are enzyme reactivators used in treating poisoning with organophosphorus cholinesterase (AChE) inhibitors. The oxime dose which can be safely administered is limited by the intrinsic toxicity of the substances such as their own AChE-inhibiting tendency. Clinical experience with the available oximes is disappointing. To meet this need, new AChE reactivators of potential clinical utility have been developed. The purpose of the study was to estimate in vitro both the intrinsic toxicity and the extent of possible protection conferred by established (pralidoxime, obidoxime, HI-6, methoxime, trimedoxime) and experimental (K-type) oximes, using diisopropyl-fluoro-phosphate (DFP) as an AChE inhibitor. The IC50 of DFP against human red blood cell AChE was determined ( approximately 120 nm). Measurements were then repeated in the presence of increasing oxime concentrations, leading to an apparent increase in DFP IC50. Calculated IC50 values were plotted against oxime concentrations to obtain an IC50 shift curve. The slope of this shift curve (tan alpha) was used to quantify the magnitude of the protective effect (nm IC50 increase per microm oxime). We show that, in the case of a linear relationship between oxime concentration and IC50, the binding constant K, determined using the Schild equation, equals IC50/DFP/tan alpha. Based on the values of tan alpha and of the binding constant K, some of the new K-oxime reactivators are far superior to pralidoxime (tan alpha = 0.8), obidoxime (1.5), HI-6 (0.8), trimedoxime (2.9) and methoxime (5.9), with K-107 (17), K-108 (20), and K-113 (16) being the outstanding compounds.


Subject(s)
Acetylcholinesterase/metabolism , Antidotes/pharmacology , Cholinesterase Inhibitors/toxicity , Cholinesterase Reactivators/pharmacology , Erythrocytes/drug effects , Isoflurophate/toxicity , Oximes/pharmacology , Antidotes/metabolism , Antidotes/toxicity , Cholinesterase Reactivators/metabolism , Cholinesterase Reactivators/toxicity , Dose-Response Relationship, Drug , Erythrocytes/enzymology , Female , Humans , Male , Models, Biological , Oximes/metabolism , Oximes/toxicity , Protein Binding
2.
J Appl Toxicol ; 27(2): 168-75, 2007.
Article in English | MEDLINE | ID: mdl-17265452

ABSTRACT

Oximes are cholinesterase reactivators of use in poisoning with organophosphorus ester enzyme inhibitors. Pralidoxime (PRX) is the oxime used in the United States. Clinical experience with pralidoxime (and other oximes) is disappointing and the routine use has been questioned. Furthermore oximes are not equally effective against all existent enzyme inhibitors. There is a clear demand for 'broad spectrum' cholinesterase reactivators with a higher efficacy than those clinically available. To meet this need over the years new reactivators of cholinesterase of potential clinical utility have been developed. The purpose of the study was to quantify 'in vitro' the extent of protection conferred by available (pralidoxime and methoxime) and experimental (K-27, K-33 and K-48) oximes, using methyl-paraoxon (methyl-POX) as an esterase inhibitor and to compare the results with those previously obtained using paraoxon (POX) as an inhibitor. Red blood cell (RBC) acetylcholinesterase (AChE) activities in whole blood were measured photometrically in the presence of different methyl-POX concentrations and IC(50) values calculated. Determinations were repeated in the presence of increasing oxime concentrations. The IC(50) of methyl-POX (59 nm) increased with the oxime concentration in a linear manner. The calculated IC(50) values were plotted against the oxime concentrations to obtain an IC(50) shift curve. The slope of the shift curve (tg alpha) was used to quantify the magnitude of the protective effect (nm IC(50) increase per microm reactivator). Based on our determinations the new K-series of reactivators is superior to pralidoxime (tg alpha = 1.9) and methoxime (tg alpha = 0.7), K-27 and K-48 being the outstanding compounds with a tg alpha value of 10 (nm IC(50) increase per microm reactivator), which is approximately five times the reactivator ability of PRX. The tg alpha value determined for K-33 was 6.3. The ranking of reactivator potencies of the examined oximes determined with methyl-POX as an inhibitor (K-27 = K-48 > K-33 > pralidoxime > methoxime) is similar to the ranking previously reported by us using POX as an inhibitor (K-27 > or = K-48 > K-33 > methoxime = pralidoxime). There is an (expected) inverse relationship between the binding constant K and the slope of the IC(50) shift curve (tg alpha) for all oximes examined. K-27 and K-48 (the most protective substances judging by the tg alpha) having the lowest K value (highest affinity). In vivo testing of the new oximes as methyl-paraoxon protective agents is necessary.


Subject(s)
Cholinesterase Inhibitors/toxicity , Cholinesterase Reactivators/pharmacology , Erythrocytes/drug effects , Oximes/pharmacology , Paraoxon/analogs & derivatives , Cholinesterase Reactivators/chemistry , Drug Antagonism , Erythrocytes/enzymology , Female , Humans , In Vitro Techniques , Inhibitory Concentration 50 , Male , Oximes/chemistry , Paraoxon/toxicity , Pralidoxime Compounds/pharmacology , Pyridinium Compounds/pharmacology , Quantitative Structure-Activity Relationship
3.
Toxicol Appl Pharmacol ; 219(2-3): 235-40, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17056080

ABSTRACT

Recently, the FDA approved the medical use of oral pyridostigmine as prophylactic treatment of possible nerve agent exposure: the concept is to block the cholinesterase transitorily using the carbamate (pyridostigmine) in order to deny access to the active site of the enzyme to the irreversible inhibitor (nerve agent) on subsequent exposure. We have shown previously that tiapride is in vitro a weak inhibitor of acetylcholinesterase and that in rats administration of tiapride before the organophosphate paraoxon significantly decreases mortality. The purpose of the present study was to compare tiapride- and pyridostigmine-based pretreatment strategies, either alone or in combination with pralidoxime reactivation, by using a prospective, non-blinded study in a rat model of acute high-dose paraoxon exposure. Groups 1-6 received 1 microMol paraoxon (approximately LD75) groups 2-6 received in addition: G(2)50 microMol tiapride 30 min before paraoxonG(3)50 microMol tiapride 30 min before paraoxon and 50 microMol pralidoxime 1 min after paraoxon G41 microMol pyridostigmine 30 min before paraoxon G(5)1 microMol pyridostigmine 30 min before paraoxon and 50 microMol pralidoxime 1 min after paraoxon G(6)50 microMol pralidoxime 1 min after paraoxon. Mortality data were compared using Kaplan-Meier plots and logrank tests. Mortality is statistically significantly influenced by all treatment strategies. Tiapride pretreatment followed by pralidoxime treatment (G3) is aux par with pyridostigmine pretreatment followed by pralidoxime treatment (G5). Tiapride pretreatment only (G2) is inferior to pyridostigmine pretreatment only (G4). The best results are achieved with pyridostigmine pretreatment only or pralidoxime treatment only (G4 and G6).


Subject(s)
Cholinesterase Inhibitors/therapeutic use , Paraoxon/poisoning , Pyridostigmine Bromide/therapeutic use , Tiapamil Hydrochloride/therapeutic use , Acute Disease , Animals , Binding, Competitive , Cholinesterase Inhibitors/administration & dosage , Cholinesterase Inhibitors/pharmacology , Cholinesterases/metabolism , Dose-Response Relationship, Drug , Drug Administration Schedule , Paraoxon/pharmacokinetics , Poisoning/enzymology , Poisoning/prevention & control , Pyridostigmine Bromide/administration & dosage , Pyridostigmine Bromide/pharmacology , Rats , Rats, Wistar , Tiapamil Hydrochloride/administration & dosage , Tiapamil Hydrochloride/pharmacology
4.
Pharmazie ; 61(3): 179-82, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16599255

ABSTRACT

Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the acetylcholinesterase inhibitor tacrine. H3 receptor antagonism, inhibition of metabolisation of neuronal histamine as well as inhibition of hydrolysis of acetylcholine are each one believed to improve reduced cognitive functions, which is useful for symptomatic treatment of Alzheimer's disease. Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of acetylcholinesterase and of butyrylcholinesterase which is another catalytic enzyme hydrolysing acetylcholine. Some compounds with (sub)nanomolar activities on the histamine-related targets are also active in the nanomolar concentration range on both cholinesterase targets being 5- to 40-times more potent than tacrine. Preliminary structure-activity relationships could already be drawn from the small number of compounds. The compounds acting as hybrid drugs simultaneously on four different targets to enhance cognitive functions via different pathways are promising lead structures for a new approach in the treatment of Alzheimer's disease.


Subject(s)
Cognition/drug effects , Histamine Antagonists/pharmacology , Receptors, Histamine H3/drug effects , Acetylcholinesterase/blood , Acetylcholinesterase/metabolism , Butyrylcholinesterase/blood , Butyrylcholinesterase/metabolism , Histamine Antagonists/metabolism , Histamine N-Methyltransferase/antagonists & inhibitors , Humans , In Vitro Techniques , Receptors, Histamine H3/metabolism , Structure-Activity Relationship
5.
Mol Cell Biochem ; 285(1-2): 79-86, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16479322

ABSTRACT

INTRODUCTION: Accidental and suicidal exposures to organophosphorus compounds (OPC) are frequent. The inhibition of esterases by OPC leads to an endogenous ACh poisoning. Recently, the FDA approved, based on animal experiments, for military combat medical use oral pyridostigmine (PSTG) for pre-exposure treatment of soman; the concept is to block the cholinesterase reversibly using the carbamate pyridostigmine in order to deny access to the active site of the enzyme to the irreversible inhibitor (OPC) on subsequent exposure. We have shown previously that tiapride (TIA) is in vitro a weak inhibitor of AChE. We also have shown recently that in rats coadministration of TIA with the organophosphate paraoxon significantly decreases mortality without having an impact on red blood cell cholinesterase (RBC-AChE) activity. PURPOSE OF THE STUDY: To establish in a prospective, non-blinded study in a rat model of acute high dose OPC (paraoxon; POX) exposure the ideal point in time for TIA pre-treatment administration and to correlate it with measured TIA plasma levels. MATERIAL AND METHODS: There were six groups of rats in each cycle of the experiment and each group contained six rats. The procedure was repeated twelve times (cycles) (n = 72 for each arm; half male and half female). All substances were applied ip. All groups (1-6) received 1 microMol POX ( approximately LD(75)); groups 1-5 also received 50 microMol TIA at different points in time. Group 1 (G(1)): TIA 120 min before POX Group 2 (G(2)): TIA 90 min before POX, Group 3 (G(3)): TIA 60 min before POX, Group 4 (G(4)): TIA 30 min before POX, Group 5 (G(5)): TIA & POX simultaneously, Group 6 (G(6)): POX only. The animals were monitored for 48 hours and mortality/survival times were recorded at 30 min, 1, 2, 3, 4, 24 and 48 h. AChE activities were determined at 30 min, 24 and 48 h in surviving animals. Statistical analysis was performed on the mortality data, cumulative survival times and enzyme activity data. Mortality data was compared using Kaplan-Meier plots. Cumulative survival times and enzyme activites were compared using the Mann-Whitney rank order test. No Bonferroni correction for multiple comparisons was applied and an alpha < or= 0.05 was considered significant. RESULTS: Mortality is statistically significantly reduced by TIA pre-treatment at all points-in-time. Highest protection is achieved if TIA is given 90 to 0 min before OPC exposure. The reduction in mortality is not correlated to TIA plasma levels (C (max) approximately 120 min post ip-administration). TIA pre-treatment is not affecting AChE activity regardless of the timing of administration. CONCLUSION: The lack of correlation between TIA plasma levels and degree of mortality reduction as well as the lack of protective effect on enzyme activity seem to indicate that the site of action of TIA is not the blood. While our hypothesis that TIA would protect AChE in a pyridostigmine-like manner (via protection of the enzyme) could not be confirmed, the reduction in mortality with TIA pre-treatment is nevertheless of potential interest.


Subject(s)
Drug Administration Schedule , Paraoxon/poisoning , Tiapamil Hydrochloride/administration & dosage , Animals , Cholinesterases/metabolism , Erythrocytes/enzymology , Female , Male , Prospective Studies , Rats , Rats, Wistar , Survival Analysis , Tiapamil Hydrochloride/blood , Tiapamil Hydrochloride/pharmacology , Time Factors
6.
J Appl Toxicol ; 26(1): 64-71, 2006.
Article in English | MEDLINE | ID: mdl-16193529

ABSTRACT

Oximes are cholinesterase reactivators of use in poisoning with organophosphorus compounds. Pralidoxime (PRX) is used clinically as an adjunct to atropine in such exposure. Clinical experience with PRX (and other oximes) is, however, disappointing and routine use has been questioned. In addition it is known that oximes are not equally effective against all existing organophosphorus compounds. There is a clear demand for 'broad spectrum' cholinesterase reactivators with a higher efficacy than PRX. Over the years new reactivators of cholinesterase of potential clinical utility have been developed. Their chemical structures were derived from those of existing esterase reactivators, especially pralidoxime, obidoxime and HI-6. The purpose of the study was to quantify in vitro the extent of oxime (pralidoxime, K-27, K-33, K-48, methoxime and BI-6) conferred protection, using paraoxon as an inhibitor. Paraoxon (POX), the active metabolite of parathion (O,O-diethyl-O-p-nitro-phenyl phosphorothioate) is a non-neuropathic organophosphate. Red blood cell (RBC) acetylcholinesterase (AChE) activities in whole blood were measured photometrically in the presence of different POX concentrations and the IC50 was calculated. Determinations were repeated in the presence of increasing oxime concentrations. The IC50 of POX increases with the oxime concentration in a linear manner. The calculated IC50 values were plotted against the oxime concentrations to obtain an IC50 shift curve. The slope of the shift curve (tg alpha) was used to quantify the magnitude of the protective effect (nm IC50 increase per microm reactivator). Based on our determinations the new K series of reactivators is far superior to pralidoxime, methoxime and BI-6, K-27 being the outstanding compound with a tg alpha value of 3.7 (nm IC50 increase per microm reactivator) which is approximately 13 times the reactivator ability of PRX. In general there is an (expected) inverse relationship between the binding constant K and the slope of the IC50 shift curve (tg alpha) for all oximes examined. K-27 (the most protective substance judging by the tg alpha) has the lowest K value (highest affinity). In vivo testing of the new oximes as an organophosphate protective agent is necessary.


Subject(s)
Acetylcholinesterase/metabolism , Cholinesterase Reactivators/pharmacology , Erythrocytes/drug effects , Oximes/pharmacology , Cholinesterase Inhibitors/toxicity , Erythrocytes/metabolism , Female , Humans , In Vitro Techniques , Inhibitory Concentration 50 , Male , Paraoxon/toxicity
7.
J Appl Toxicol ; 25(6): 562-7, 2005.
Article in English | MEDLINE | ID: mdl-16193528

ABSTRACT

Weak and reversible inhibitors of cholinesterases, when administered before potent organophosphorus inhibitors (pretreatment), have the ability, to a certain extent, to protect enzymes from inhibition. Such a protective effect was demonstrated in vitro for metoclopramide and ranitidine. The putative mode of protective action of these substances is, when administered in excess, competition for the active site of the enzyme with the more potent organophosphate. The present paper presents results using another benzamide with weak cholinesterase inhibitory properties: tiapride (TIA). The purpose of the study was to quantify in vitro the extent that TIA conferred protection, using paraoxon (POX) as an inhibitor, and to compare the results with existing data obtained using TIA as a protective agent against dichlorvos (DDVP). POX is a highly toxic non-neuropathic organophosphate. While the use of parathion (the inactive prodrug which is metabolically converted to POX) has been restricted in most countries, the organophosphate is still responsible for a large number of accidental or suicidal exposures. DDVP is a moderately toxic, non-neuropathic organophosphate. Red blood cell (RBC) acetylcholinesterase (AChE) activities in whole blood and butyrylcholinesterase (BChE) activities in human plasma were measured photometrically in the presence of different POX and TIA concentrations and the IC(50) was calculated. Determinations were repeated in the presence of increasing TIA concentrations. The IC(50) of POX increases with the TIA concentration in a linear manner. The protective effect of tiapride on cholinesterase could be of practical relevance in the pretreatment of organophosphate poisoning. It is concluded that in vivo testing of TIA as an organophosphate protective agent is warranted.


Subject(s)
Acetylcholinesterase/metabolism , Cholinesterase Inhibitors/pharmacology , Dopamine Antagonists/pharmacology , Paraoxon/toxicity , Tiapamil Hydrochloride/pharmacology , Acetylcholinesterase/blood , Binding, Competitive , Butyrylcholinesterase/blood , Butyrylcholinesterase/metabolism , Cholinesterase Inhibitors/administration & dosage , Cholinesterase Inhibitors/toxicity , Dopamine Antagonists/administration & dosage , Dose-Response Relationship, Drug , Erythrocytes/drug effects , Erythrocytes/enzymology , Humans , Inhibitory Concentration 50 , Kinetics , Tiapamil Hydrochloride/administration & dosage
8.
Int J Toxicol ; 24(2): 79-86, 2005.
Article in English | MEDLINE | ID: mdl-16036766

ABSTRACT

Metoclopramide is a benzamide dopamine receptor antagonist and serotonine receptor agonist widely used as an antiemetic and gastric prokinetic drug. In addition, metoclopramide is a weak and reversible inhibitor of cholinesterases. The authors have previously shown that metoclopramide has a cholinesterase protective effect against inhibition by organophosphates (OPs). The putative mode of protective action of metoclopramide is, when administered in excess, competion for the active site of the enzyme with the more potent OP. In the present paper the authors present their results using another benzamide with weak cholinesterase inhibitory properties, tiapride (TIA). The purpose of the study was to quantify in vitro the extent of TIA-conferred protection, using dichlorvos (dichlorovinyl dimethyl phosphate; DDVP) as an inhibitor. DDVP is a moderately toxic (LD50 in rats in the milligram range), non-neuropathic OP. The substance is responsible for a large number of accidental or suicidal exposures. Red blood cell (RBC) acetylcholinesterase (AChE) activities in whole blood and butyrylcholinesterase (BChE) activities in human plasma were measured photometrically in the presence of different DDVP and TIA concentrations and IC50 was calculated. Determinations were repeated in the presence of increasing TIA concentrations. The IC50 of DDVP increases with the TIA concentration in a linear manner. The protective effect of TIA on cholinesterase could be of practical relevance in the treatment of OP poisoning. The authors conclude that in vivo testing of TIA as an OP protective agent is warranted.


Subject(s)
Acetylcholinesterase/metabolism , Cholinesterase Inhibitors/toxicity , Dichlorvos/toxicity , Erythrocytes/drug effects , Tiapamil Hydrochloride/pharmacology , Acetylcholinesterase/blood , Binding, Competitive , Butyrylcholinesterase/blood , Butyrylcholinesterase/metabolism , Cholinesterase Inhibitors/metabolism , Chromatography, Gas , Dichlorvos/metabolism , Dose-Response Relationship, Drug , Erythrocytes/enzymology , Female , Humans , In Vitro Techniques , Male , Tiapamil Hydrochloride/metabolism
9.
J Appl Toxicol ; 25(1): 60-7, 2005.
Article in English | MEDLINE | ID: mdl-15669026

ABSTRACT

Metoclopramide (MCP) is a dopamine receptor antagonist and serotonin receptor agonist widely used as an antiemetic and gastric prokinetic drug. In addition MCP is a weak and reversible inhibitor of cholinesterases. We have shown that MCP has a cholinesterase protective effect against inhibition by organophosphates. The putative mode of protective action of MCP is competition for the active site of the enzyme with the more potent organophosphate. In the present paper we present our results using another weak inhibitor of cholinesterases: ranitidine (RAN). The purpose of the study was to quantify in vitro the extent of RAN-conferred protection, using paraoxon (POX) as an inhibitor. Paraoxon is a non-neuropathic organophosphate responsible for a large number of accidental or suicidal exposures. Red blood cell (RBC) acetylcholinesterase (AChE) activities in whole blood and butyrylcholinesterase (BChE) activities in human plasma were measured photometrically in the presence of different POX and RAN concentrations and the IC50 was calculated. Determinations were repeated in the presence of increasing RAN concentrations. The IC50 shift induced by the presence of RAN increases with the RAN concentration in a linear manner. The shift was more pronounced with RBC-AChE. The protective effect of RAN on cholinesterase could be of practical relevance in the treatment of POX poisoning. We conclude that in vivo testing of RAN as an organophosphate protective agent is warranted.


Subject(s)
Acetylcholinesterase/metabolism , Cholinesterase Inhibitors/toxicity , Cholinesterases/blood , Erythrocytes/drug effects , Paraoxon/toxicity , Ranitidine/pharmacology , Butyrylcholinesterase/metabolism , Erythrocytes/enzymology , Humans , Inhibitory Concentration 50
10.
J Appl Toxicol ; 25(1): 68-73, 2005.
Article in English | MEDLINE | ID: mdl-15669039

ABSTRACT

Weak and reversible inhibitors of cholinesterase, when coadministred in excess with a more potent inhibitor such as organophosphates, can act in a protective manner. Ranitidine (RAN) is a clinically widely used histamine type 2 (H2) receptor blocker. Ranitidine is also the most potent inhibitor of acetylcholinesterase among H2 blockers (inhibitory constant K in the low micromolar range) but roughly three orders of magnitude less potent than paraoxon. This study evaluates RAN-conferred protection in acute high-dose organophosphate (paraoxon, POX) exposure in rats in direct comparison with the therapeutic gold-standard pralidoxime (PRX). Group 1 received 1 microM POX, group 2 received 50 microM RAN, group 3 received 50 microM PRX, group 4 received 1 microM POX + 50 microM RAN and group 5 received 1 microM POX + 50 microM PRX. All substances were applied intraperitoneally. The animals were monitored for 48 h and mortality was recorded at 30 min and 1, 2, 3, 4, 24 and 48 h. Blood was taken for red blood cell acetylcholinesterase (RBC-AChE) measurements at baseline, 30 min and 24 and 48 h. Mortality occurred mainly in the fi rst 30 min after POX administration, with minimal changes occurring thereafter. Mortality (in %) at 30 min in groups 1, 4 and 5 was 52 +/- 18, 37 +/- 20 and 17 +/- 18, respectively, and mortality at 48 h was 59 +/- 12, 39 +/- 20 and 28 +/- 20, respectively. The RBC-AChE activities (in % of baseline values) at 30 min in groups 1, 4 and 5 were 18 +/- 16, 47 +/- 23 and 48 +/- 20, respectively. At 24 h the values were 46 +/- 16, 65 +/- 24 and 86 +/- 17, respectively, and at 48 h the values were 71 +/- 19, 78 +/- 21 and 110 +/- 27, respectively. Coadministration of PRX significantly decreases mortality in the described model at all points in time. Coadministration of RAN statistically significantly decreases mortality at 24 and 48 h. The extent of protection conferred by RAN is less (but not statistically significantly so) than that conferred by the gold-standard PRX. Coadministration of PRX statistically significantly increases RBC-AChE activities in the described model at all points in time. Ranitidine confers a statistically significant protection for the enzyme at 30 min only. We conclude that RAN is potentially of clinical use in reducing mortality in acute high-dose organophosphate exposure. Further studies involving different organophosphates and dosages, as well as different animal species, will be needed both to con fi rm these initial findings and to address the issue of the optimal timing for RAN preadministration.


Subject(s)
Organophosphorus Compounds/antagonists & inhibitors , Organophosphorus Compounds/toxicity , Pralidoxime Compounds/therapeutic use , Protective Agents/therapeutic use , Ranitidine/therapeutic use , Animals , Erythrocytes/drug effects , Erythrocytes/enzymology , Rats , Rats, Wistar , Time Factors
11.
J Appl Toxicol ; 24(4): 257-60, 2004.
Article in English | MEDLINE | ID: mdl-15300712

ABSTRACT

The benzamide compound metoclopramide (MCP) protects against cholinesterase inhibition by paraoxon (POX) both in vitro and in vivo. This study evaluates MCP-conferred protection of enzyme activity head to head against the therapeutic gold standard pralidoxime (PRX). Six groups of rats were used. All substances were applied i.p. daily for 5 days, followed by a 2-day rest. The 7-day cycle was repeated eight times. Group 1 received 100 nM POX, group 2 received 50 micro M MCP, group 3 received 100 nM POX + 50 micro M MCP, group 4 received 50 micro M PRX, group 5 received 100 nM POX + 50 micro M PRX and group 6 received saline. Red blood cell acetylcholinesterase (RBC-AChE) measurements were performed at baseline and on day 5 of each 7-day cycle. The sums of enzyme activities over time (weekly values expressed as % of baseline of 100%) were compared using the Mann-Whitney rank order test. A Bonferroni correction of 4 for multiple comparisons was applied. Paraoxon significantly reduced enzyme activities when compared with saline (Sigma = 535 +/- 25 vs 902 +/- 42). Metoclopramide conferred statistically significant in vivo protection from inhibition of RBC-AChE by POX (Sigma = 640 +/- 58). The extent of protection was significantly less than that conferred by the gold standard PRX (Sigma = 765 +/- 57). Metoclopramide, in addition to being less effective as an RBC-AChE protective agent, also caused a failure to thrive in the POX+MCP-exposed rats, as evidenced by the changes in body weight.


Subject(s)
Acetylcholinesterase/metabolism , Cholinesterase Inhibitors/toxicity , Cholinesterase Reactivators/pharmacology , Metoclopramide/pharmacology , Paraoxon/toxicity , Pralidoxime Compounds/pharmacology , Animals , Body Weight/drug effects , Cholinesterase Reactivators/administration & dosage , Erythrocytes/drug effects , Erythrocytes/enzymology , Injections, Intraperitoneal , Male , Metoclopramide/administration & dosage , Pralidoxime Compounds/administration & dosage , Rats
12.
J Appl Toxicol ; 24(2): 143-6, 2004.
Article in English | MEDLINE | ID: mdl-15052610

ABSTRACT

Metoclopramide (MCP) is a dopamine receptor antagonist and serotonin receptor agonist widely used as an antiemetic and gastric prokinetic drug. In addition MCP is a reversible inhibitor of cholinesterases from human central nervous system and blood. Metoclopramide may have a cholinesterase protective effect against inhibition by organophosphates. The purpose of the study was to quantify in vitro, by means of the IC(50) shift, the extent of MCP conferred protection, using mipafox (MPFX) as an inhibitor. Mipafox is a neuropathic organophosphate. Cholinesterase activities (with acetylthiocholine [ChE-A] and butyrylthiocholine [ChE-B] as substrates) in human plasma were measured photometrically in the presence of different MPFX concentrations and the IC(50) was calculated. Determinations were repeated in the presence of increasing MCP concentrations. It appears that the shift induced by the presence of MCP increases with the MCP concentration in a linear manner. In the presence of a clinically easily achievable plasma concentration of 1 micro M MCP, the IC(50) of MPFX for cholinesterase 'shifts' by a factor of ca. 3-6. The protective effect of MCP on cholinesterase could be of practical relevance in the treatment of organophosphate poisoning. We conclude that in vivo testing of MCP as an organophosphate protective agent is warranted.


Subject(s)
Cholinesterase Inhibitors/toxicity , Cholinesterases/blood , Dopamine Antagonists/pharmacology , Isoflurophate/analogs & derivatives , Isoflurophate/toxicity , Metoclopramide/pharmacology , Dose-Response Relationship, Drug , Drug Antagonism , Humans , In Vitro Techniques , Inhibitory Concentration 50
13.
Cell Mol Life Sci ; 60(6): 1172-9, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12861383

ABSTRACT

This study examined the changes occurring in the pattern of distribution and expression of neuronal nitric oxide synthase (nNOS)-positive nerves in the gastroduodenal tract of streptozotocin-induced diabetic rats. The ganglion cells of the myenteric plexus of the gastric antrum of normal rats contain nNOS. We also observed nNOS-positive neurons and fibres in the myenteric plexus of the duodenum of normal rats. After the onset of diabetes, the number and intensity of staining of nNOS-positive nerve profiles in the gastric antrum and duodenum did not change significantly. However, Western blotting showed a significant increase in the expression of nNOS after the onset of diabetes. In conclusion, diabetes of 4 and 32 weeks duration induced an increase in the tissue content of nNOS in the gastroduodenum of rat. The increase in the level of nNOS in the gastroduodenum of diabetic rats may explain why impaired gastric emptying is common in patients with diabetes.


Subject(s)
Diabetes Mellitus, Experimental/enzymology , Duodenum/enzymology , Nitric Oxide Synthase/metabolism , Stomach/enzymology , Animals , Diabetes Mellitus/physiopathology , Duodenum/innervation , Gastric Emptying/physiology , Gastrointestinal Motility/physiology , Humans , Male , Myenteric Plexus/enzymology , Nitric Oxide/biosynthesis , Nitric Oxide Synthase Type I , Rats , Rats, Wistar , Stomach/innervation
14.
Arch Gynecol Obstet ; 265(3): 141-7, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11561743

ABSTRACT

To compare the inhibitory effects of a new group of smooth muscle relaxants, the potassium channel openers cromakalim and pinacidil, with those of oxybutynin on detrusor muscle stimulation in animals. Detrusor strips of guinea pigs (n=16) and rabbits (n=20) were mounted in organ bath for recording of isometric tension. Alpha,beta-methylene ATP (10(-7), 10(-6), 10(-5) M), carbachol (10(-6), 10(-5), 3 x 10(-5), 5 x 10(-5) M) and transmural electrical-field stimulation (TES) were applied and concentration-response curves in the absence or presence of cromakalim (10(-6), 10(-5) M), pinacidil (10(-5), 5 x 10(-5) M) and oxybutynin (10(-5), 5 x 10(-5) M) were generated. All curves were displaced to the right in a concentration-dependent manner. The order of potency of inhibition was as follows: alpha,beta-methylene ATP (pinacidil>oxybutynin>cromakalim in guinea pigs; pinacidil>cromakalim>oxybutynin in rabbits); TES (pinacidil>cromakalim>oxybutynin in guinea pigs; cromakalim>oxybutynin>pinacidil in rabbits); carbachol (oxybutynin>pinacidil>cromakalim in guinea pigs; oxybutynin>cromakalim>pinacidil in rabbits). Cromakalim and pinacidil mainly inhibited purinergic-induced (alpha,beta-methylene ATP and TES) detrusor contractions.


Subject(s)
Cholinergic Antagonists/therapeutic use , Cromakalim/therapeutic use , Mandelic Acids/therapeutic use , Muscle, Smooth/drug effects , Pinacidil/therapeutic use , Urinary Bladder/drug effects , Vasodilator Agents/therapeutic use , Animals , Guinea Pigs , In Vitro Techniques , Rabbits
15.
Eur J Gastroenterol Hepatol ; 9(4): 381-8, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9160202

ABSTRACT

OBJECTIVE AND DESIGN: The normal aborad propagation of the slow wave in the small intestine is easily distorted by pacing, hypoxia or transection. We studied whether acute local ischaemia would also induce serious conduction disturbances and ectopic pacemaking. METHODS: After general anaesthesia and a mid-abdominal incision, a multi-electrode array of 240 extracellular electrodes was positioned on the serosal surface of an exteriorized intestinal loop. Simultaneous recordings of all 240 surface electrodes was performed during a control period and for 5-10 min following local acute arterial occlusion. After the experiments activation maps were constructed describing the pattern of propagation of the slow waves. RESULTS: During control periods, the activation maps showed homogeneous aborad conduction of the slow wave. During acute ischaemia, local areas of inexcitability developed rapidly, merging together to form lines of conduction block. This in turn often provoked the appearance of subsidiary ectopic pacemakers. The location of the conduction blocks as well as that of ectopic pacemakers was highly variable and could disappear and reappear at other sites. CONCLUSION: Within minutes, acute ischaemia disturbed the organized homogeneous aborad propagation of the slow wave leading to pronounced inhomogeneous depression of conduction, local inexcitability, conduction block and the appearance of subsidiary pacemakers.


Subject(s)
Electrophysiology/methods , Gastrointestinal Motility/physiology , Intestine, Small/blood supply , Ischemia/physiopathology , Acute Disease , Animals , Cats , Disease Models, Animal , Electric Conductivity , Electric Stimulation , Female , Male
16.
Neurogastroenterol Motil ; 8(3): 207-16, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8878080

ABSTRACT

High resolution electrical mapping in the gastrointestinal system entails recording from a large number of extracellular electrodes simultaneously. It allows the collection of signals from 240 individual sites which are then amplified, filtered, digitized, multiplexed and stored on tape. After recording, periods of interest can be analysed and the original sequence of activity reconstructed. This technology, originally developed to study normal rhythms and abnormal dysrhythmias in the heart, has been modified to allow recordings from the gastrointestinal tract. In this report, initial results are presented describing the origin and propagation of the slow wave in the isolated stomach and the isolated duodenum in the cat. These results show that in both organs it not uncommon to have more than one focus active during a single cycle. The conduction of slow waves from such a multiple pacemaker environment can become quite complex, and this may play a role in determining the contractile pattern in these organs.


Subject(s)
Digestive System Physiological Phenomena , Duodenum/physiology , Electrophysiology/methods , Stomach/physiology , Animals , Cats , Electric Conductivity , Electrophysiology/instrumentation , Female , In Vitro Techniques , Male , Muscle, Smooth/physiology , Myoelectric Complex, Migrating , Time Factors
17.
Am J Physiol ; 270(4 Pt 2): F567-74, 1996 Apr.
Article in English | MEDLINE | ID: mdl-8967335

ABSTRACT

In renal pelvis preparations isolated from the sheep, the location of the pacemaker and the pathway of conduction of the electrical impulse in the pelvis were analyzed in detail. An electrophysiological acquisition system was used allowing simultaneous recordings from 240 extracellular electrodes. Reconstruction of the spread of activity showed that the site of the pelvis pacemaker was, in virtually all cases, located at the pelvicalyceal border and never in the body of the pelvis or in the area of the pelviureteric junction. One single pacemaker was responsible for a particular spread of activation, and fusion of activity originating from two or more pacemakers did not place. Furthermore, spontaneous shifts of the pacemaker could occur from one site to another along the pelvicalyceal border. Conduction from the site of the current pacemaker to the pelviureteric junction and the ureter was slow, inhomogeneous, and contorted. Multiple instances of partial or total conduction block were seen at all levels in the pelvis and were not restricted to the pelviureteric junction. The occurrence of the conduction block did not seem to be related to the length of the preceding interval, implying that the refractory period did not play a major role in the genesis of intrapelvic conduction block. In conclusion, high-resolution mapping of the renal pelvis is possible and reveals location and behavior of the pacemaker and documents inhomogeneities in conduction and conduction block.


Subject(s)
Kidney Pelvis/innervation , Neural Conduction , Animals , Electrophysiology , In Vitro Techniques , Nervous System Physiological Phenomena , Sheep , Time Factors
18.
Med Biol Eng Comput ; 33(3 Spec No): 476-81, 1995 May.
Article in English | MEDLINE | ID: mdl-7666697

ABSTRACT

High-resolution mapping makes it possible to reconstruct and display the conduction pattern of the action potential as it propagates through cardiac or smooth muscles. During slow and regular activity, time mapping of the spread of activation muscles. During slow and regular activity, time mapping of the spread of activation is relatively simple and straightforward. However, when frequencies are high or conduction is slow, such as seen during atrial fibrillation or found in the pregnant uterus, the tracking of individual waves may become more difficult and uncertain. In order to reconstruct the pathway of a single wave, a search and sorting routine was developed which makes it possible to distinguish, track and display individual wavelets. The algorithm is able to detect variations in conduction block, spontaneous shifts in the location of the pacemaker and changes in the direction of conduction. It is less sensitive when two or more wavefronts intermingle in space and time, such as during collision or fusion. Wave mapping is especially useful, in addition to current time mapping, in sorting quickly through the large amount of data produced by high-resolution mapping of electrical activities in cardiac and smooth muscle.


Subject(s)
Body Surface Potential Mapping , Myometrium/physiology , Action Potentials/physiology , Algorithms , Animals , Female , Muscle, Smooth/physiology , Rats , Uterine Contraction/physiology
19.
Am J Physiol ; 267(5 Pt 1): C1210-23, 1994 Nov.
Article in English | MEDLINE | ID: mdl-7977684

ABSTRACT

Detailed spatial analysis of propagation of individual action potential was performed during spontaneous bursts of activity in the isolated 17-day pregnant rat myometrium. Use was made of high-resolution mapping with simultaneous recordings from 240 extracellular electrodes. Positioning of the electrode assembly by itself did not have any adverse effects, and no differences were found in the period or duration of spontaneous bursts recorded with and without the electrode assembly touching the tissue. The spread of propagation of individual action potentials was reconstructed at several moments during myometrial spike bursts. Both the direction and the sequence of activation of the myometrium were found to be highly variable and depended on 1) the level and spatial dispersion of excitability and 2) whether conduction occurred predominantly in the longitudinal or the circumferential direction. Furthermore, conduction was frequently complicated by the spontaneous occurrence of 1) lines of conduction block, 2) focal sites of pacemaking, or 3) merging of two or more wavelets into a single wave. In contrast, when the myometrium was divided into small segments, activity became much more regular, and both the location of the pacemaker and the direction of propagation were much more stable than in the whole myometrium. In conclusion, spontaneous spatial variations in local spike propagation at the preterm stage could provide for the necessary asynchrony in activation and play a role in the prevention of forceful contractions and premature labor.


Subject(s)
Myometrium/physiology , Pregnancy, Animal/physiology , Action Potentials , Animals , Female , Pregnancy , Rats , Rats, Wistar , Time Factors , Uterus/physiology
20.
J Appl Physiol (1985) ; 74(3): 1454-61, 1993 Mar.
Article in English | MEDLINE | ID: mdl-8482690

ABSTRACT

The technique of multiple simultaneous recordings from a large number of extracellular electrodes (> 100) is currently used in the study of normal and abnormal electrical conduction in the heart and the genesis of cardiac arrhythmias. To investigate whether such a system could also be applied in gastrointestinal electrophysiology, several studies were performed with this technique on segments of isolated rabbit duodenum. A multiple-electrode assembly consisting of 240 silver wires was positioned on the serosal surface of the duodenum, and the recorded signals were, after suitable processing, stored. Thereafter, analysis of all simultaneously recorded slow waves during a selected period of time was performed to reconstruct the pattern of conduction in the duodenum. The first results show that there is a considerable variation in conduction pattern, which is determined by the site of the natural pacemaker. Several experiments were performed to rule out possible deleterious effects of positioning the multiple-electrode assembly on the duodenum. Furthermore, prolonged periods of recording did not influence propagation speed and pattern provided that the positioning of the multiple electrode assembly was performed with care. Entrainment of the natural pacemaker was possible by applying electrical stimuli through 2 of the 240 extracellular electrodes during simultaneous recordings. In conclusion, multisite extracellular mapping of gastrointestinal smooth muscle is possible and can be used to study origin and spread of slow-wave activity.


Subject(s)
Duodenum/physiology , Muscle, Smooth/physiology , Animals , Electric Stimulation , Electrodes , Electromyography , Electrophysiology , Female , Intestinal Mucosa/physiology , Male , Rabbits
SELECTION OF CITATIONS
SEARCH DETAIL
...